Progression-Free Survival Is a Surrogate for Survival in Advanced Colorectal Cancer
Journal of Clinical Oncology2007Vol. 25(33), pp. 5218–5224
Citations Over TimeTop 10% of 2007 papers
Marc Buyse, Tomasz Burzykowski, Kevin Carroll, Stefan Michiels, Daniel J. Sargent, Langdon L. Miller, Gary Elfring, Jean‐Pierre Pignon, Pascal Piedbois
Abstract
PFS is an acceptable surrogate for OS in advanced colorectal cancer.
Related Papers
- → Phase I and pharmacokinetic study of irinotecan in combination with raltitrexed(2002)5 cited
- Application research of raltitrexed and oxaliplatin in treatment of elderly patients with advanced colorectal cancer(2014)
- Clinical Study of Ralitrexed plus Oxaliplatin versus Fluorouracil and Leucovorin plus Oxaliplatin for Advanced Colorectal Cancer(2013)
- Raltitrexed Combined With Oxaliplatin in the Treatment of 42 Cases Advanced Colorectal Cancer(2015)
- [Absence of cross resistance between an irinotecan plus cisplatin combination and raltitrexed (ZD1694) in two patients with advanced colorectal cancer].(2000)